FilingSEC EDGAR8-K
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
· SEC accepted
StagePhase 1
Filing content
The company transitioned to a clinical-stage firm, advancing the IBIO-600 Phase 1 trial and continuing development of its pipeline including IBIO-610.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…